■赛拉嗪是一种2肾上腺素能受体激动剂和兽用镇静剂,可引起严重的健康并发症,但检测和治疗人类暴露的干预措施仍不发达。基于社区的药物检查服务(DCS)涉及对少量药物的测试,以增加社区对不受管制的供应的了解并减少危害。这项研究的特点是赛拉嗪的意识,欲望,在罗德岛州使用毒品(PWUD)的人群中使用和暴露,US.
■我们分析了一项正在进行的PWUD队列研究的数据。2023年,对125名PWUD进行了登记和调查。使用即时傅里叶变换红外光谱(FTIR-S),我们在现场测试了每位参与者的药物样本,并在实验室外确认了结果。结果实时传达,伴随着减少伤害的教育,转介资源和护理。
■几乎所有参与者(99.2%)都希望避免赛拉嗪的暴露。一半(51.2%)知道赛拉嗪是什么,和四分之一(26.1%)怀疑之前的风险敞口。赛拉嗪的暴露主要是通过镇静作用(45.2%)和溃疡性作用(29.0%)推测的。只有8.8%的参与者提交了他们预期含有赛拉嗪的样本。使用FTIR-S在14.5%的样品中检测到赛拉嗪,使用气相色谱质谱(GC-MS)和液相色谱四极杆飞行时间质谱(LC-QTOF-MS)的双实验室方法在21.4%的样品中检测到赛拉嗪。参与者认为这些赛拉嗪阳性样品是芬太尼(78.3%),海洛因(13.0%),或Percocet®(8.7%)。
■在减少伤害的组织中实施护理点DCS可能有助于迅速提高赛拉嗪的意识并使有风险的个人参与预防,减少危害,治疗,以及赛拉嗪相关伤口的快速护理。
UNASSIGNED: Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
UNASSIGNED: We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
UNASSIGNED: Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
UNASSIGNED: Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.